

1652

PTO/SB/82 (05-03)

Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

## REVOCATION OF POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

pond to a collection of information unless	it displays a valid OMB control number
Application Number	09/502,498
Filing Date	February 11, 2000
First Named Inventor	Andrzej Kilian
Art Unit	1652
Examiner Name	Malgorzata A Walicka
Attorney Docket Number	407C2

I hereby revoke all	previous powers of attorney or	r authorizations of age	ent given in	the above-id	entified applicat	ion: 821
☑ A power of Attorney or Authorization of Agent is submitted herewith.				RECE	VĘĎ	
OR					AUG 0 7	2003
☐ Please change	the correspondence address	for the above-identifie	d application	on to:	ECH CENTER	1600/2900
☐ Custom	er Number		-	Numb	Customer er Bar Code	
OR				La	bel here	
Firm <i>or</i>	ne ,					
Address						
Address						
City						
Country		State		Zi	P	
Telephone		Fax				
I am the:			•			
☐ Applicar	nt/Inventor.					
	e of record of the entire interesent under 37 CFR 3.73(b) is en		B/96)			
	SIGNATURE of A	pplicant or Assignee	of Recor	d		
Name Richa	rd A Jefferson					
Signature	16 Mm	-				
Date	08/01/03	Telep	+61	2 6246 45	02	
	of all the inventors or assignee ultiple forms if more than one s				entative(s) are	
☐ *Total of	forms are submitted	d.				

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/81 (05-03) Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

ired to respond to a collection of into	ormation unless it displays a valid OMB control number.
Application Number	09/502,498
Filing Date	02/11/2000
First Named Inventor	Andrzej Kilian
Title	Vertebrate telomerase genes and proteir
Art Unit	1652
Examiner Name	Malgorzata A Walicka
Attorney Docket Number	407C2

_					1.0.02	
I here	by appoint:					
	Practitioners at Custome	er Number		-		Place Customer Number Bar Code Label here
	OR		<del></del>			
	Practitioner(s) named be	elow:				RECEIVED
		Name			Registration	
ł	Carol Nottenburg	Corel Nettenburg		39317 AUG 0 7 20		
ł	Caronivolleriburg		39317			
						TECH CENTER 1600/29
						12011 0211121 1000/20
	//our attorney(s) or agent( mark Office connected th	s) to prosecute the application identified	l above, and	to tr	ansact all business	in the United States Patent and
	-	ence address for the above-identified ap	nlication to:			- 1
l m	•	·	phication to.			
<u> </u>	The above-mentioned C	ustomer Number.			Γ.	
╎┌┌	)R			_		Place Customer
	Practitioners at Custome	er Number.			<b></b>	Number Bar Code
					L	Label here
_	Pirm or	<del></del>				
X	Individual Name	Carol Nottenburg				
	Address	814 32nd Ave S				
	Address					
	City	Seattle	St	ate	WA	Zip 98144
	Country	USA			Y	
	Telephone	206 860 2120	Fa	ix	206 860 3933	
l am						<b>i</b>
	Applicant/Inventor.					
X		the entire interest. See 37 CFR 3.71. CFR 3.73(b) is enclosed. (Form PTO/SB/	/96)			
	Statement under 37 C				of Booord	
		SIGNATURE of Applican		iee o		
Name	r tionagg goog c	rson				
Signa	ture	Jess -	<del></del>		Tolophore	-01 0 0010 1500
Date		08/01,	<u>/03</u>		Telephone -	+61 2 6246 4502
	Signatures of all the inventor f more than one signature is	rs or assignees of record of the entire interest required, see below*.	or their repre	senta	tive(s) are required. S	ubmit multiple
	*Total of	forms are submitted				

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/96 (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

uction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number STATEMENT UNDER 37 CFR 3.73(b) AUG 0 7 2003
TECH CENTER 1600/2900 Applicant/Patent Owner: The Monticello Group Ltd Application No./Patent No.: 09/502,498 \_\_\_\_\_ Filed/Issue Date: 11 February 2000 Vertebrate Telomerase Genes and Proteins and Uses Thereof The Monticello Group Ltd corporation (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.) states that it is: 1. X the assignee of the entire right, title, and interest; or an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is in the patent application/patent identified above by virtue of either: A. [ ] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel , Frame , or for which a copy thereof is OR B. [x] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown 1. From: Andrzej Kilian - To: -The document was recorded in the United States Patent and Trademark Office at Reel 9379 Frame 0249 or for which a copy thereof is a \_, or for which a copy thereof is attached. \_\_, Frame <u>0249</u> To: The Monticello Group Ltd 2. From: CAMBIA The document was recorded in the United States Patent and Trademark Office at \_\_\_\_, Frame 0744 Reel 013347 \_, or for which a copy thereof is attached. To: Peter MacCallum Cancer Institute 3. From: David Bowtell The document was recorded in the United States Patent and Trademark Office at \_\_\_\_, Frame <u>02</u>49 , or for which a copy thereof is attached. Reel 9379 [x] Additional documents in the chain of title are listed on a supplemental sheet. [x ] Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08] The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. Richard A Jefferson Date +61 2 6246 4502 Sidnature Telephone number President

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Title

## STATEMENT UNDER 37 CFR 3.73(b) continu d

Applicant/Patent Owner: The Monticello Group Ltd
Application No./Patent No.: 09/502,498
Filed/Issue Date: 11 February 2000
Entitled: VERTEBRATE TELOMERASE GENES AND PROTEINS AND USES

**THEREOF** 

4. From: Peter MacCallum Cancer Institute

The Monticello Group Ltd.

A copy thereof is attached.

## ASSIGNMENT

WHEREAS, Peter MacCallum Cancer Institute (hereinafter referred to as ASSIGNOR), having a place of business at St Andrews Place, East Melbourne, VIC 3002, Australia is an owner of an invention entitled "VERTEBRATE TELOMERASE GENES AND PROTEINS AND USES THEREOF" as described and claimed in the specification for which the application was filed with the United States Patent and Trademark Office on 11 February 2000, and assigned Application No. 09/502,498.

WHEREAS, The Monticello Group Ltd (TMGL) (hereinafter referred to as ASSIGNEE), a corporation of the State of Washington having a having a registered office at Suite 3600, 1000 Second Avenue, Seattle, Washington 88104, USA, is desirous of acquiring ASSIGNOR'S entire right, title and interest in and to the invention and in and to any letters patent that may be granted therefore in the United States and in any and all foreign countries.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby assigns, transfers, and sells unto said ASSIGNEE its entire right, title and interest in and to said invention, said application and any and all letters patent that may be granted for said invention in the United States of America and its territorial possessions and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said United States application to which said foreign applications are entitled by virtue of international convention, treaty or otherwise. Said invention, application and all letters patent on said invention are to be held and enjoyed by ASSIGNEE and its successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, transfer and sale not been made. ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue all letters patent on said invention to ASSIGNEE. ASSIGNOR agrees to execute all instruments and documents required for the making and prosecution of applications for United States and foreign letters patent on said

invention, for litigation regarding letters patent, or for the purpose of protecting title to said invention or letters patent therefore.

8/7/03

Name :

PROFESSOR DAVID BOWTELL

Citle: 131

DIRECTOR (RESEARCH)
PETER MACCALLUM CANCER CENTRE

I certify that I know or have satisfactory evidence that <u>Prof. DAVID JOWN FRAL</u> signed this instrument of his own free will, as a voluntary act for the uses and purposes mentioned in the instrument.

Witness:

Date:

GENERAL MANAGER (RESEARCH)

PETER MacCALLUM CANCER INSTITUTE